Long-Acting Injectable Program Implementation Insights From Genoa Healthcare® Pharmacy

Listen

0:00 / 0:00

This educational resource was sponsored by Johnson & Johnson.

Part 2 of this educational resource provides insights for institutions seeking to implement a pharmacist-led long-acting injectable administration program for schizophrenia.

Articles in this issue

9 months ago

Article

Optimizing Long-Acting Injectable Administration for Patients Living With Schizophrenia

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Long-Acting Injectable Program Implementation Insights From Genoa Healthcare® Pharmacy

Articles in this issue

Trending on AJMC

FDA Approves First Oral Carbapenem Antibiotic for Complicated UTIs

EHA 2026 Had Something for Everyone, From Pediatric Practitioners to “Myeloma Maniacs”

Fourteen Years of HIV PrEP: How New Innovations Build on Decades of Progress in HIV

How MCOs Should Be Preparing for the OBBBA's Medicaid Cuts: David Brueggeman, MBA

5 Ongoing Clinical Trials in Myeloproliferative Neoplasms